| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $2.82 | - | - |
| Q1'26 | $2.37 | $2.50 | +5.6% |
| Q4'25 | $2.45 | $2.42 | -1.4% |
| Q3'25 | $2.50 | $2.60 | +3.9% |
| Q2'25 | $2.57 | $2.62 | +1.9% |
| Q1'25 | $2.15 | $2.21 | +2.8% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $3.0B | - | - |
| Q1'26 | $2.8B | $2.9B | +2.4% |
| Q4'25 | $2.8B | $2.8B | +0.9% |
| Q3'25 | - | $2.8B | - |
| Q2'25 | - | $2.8B | - |
| Q1'25 | - | $2.7B | - |
Market Data
DGX is currently trading at $194.12, giving Quest Diagnostics Incorporated a market cap of 21.61B and a P/E ratio of 21.1. Today's range spans $192.35–$196.00, with shares opening at $194.26 and moving down $1.09 (0.6%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 51/100.
Over the past year DGX has traded between $164.65 and $213.50 - the current price is +17.9% off the 52-week low and -9.1% from the high. 26 analysts cover the stock with a Hold consensus and a mean 12-month target of $223.44 (range $184.00–$245.00), implying upside of +15.1%.
For fundamental investors, DGX's neutral technical phase (55/100, HOLD) is an opportunity to assess valuation without the noise of trending price action. At 21.61B in Healthcare market cap The current P/E ratio stands at 21.1., neutral sentiment (51/100) and a price of $194.12 (in the middle of its 52-week range) describe a stock where the primary value driver is fundamental rather than momentum. Annual range: $164.65–$213.50.
In neutral phases, large-cap Healthcare names like DGX are often where sector rotation debates play out quietly — at 21.61B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 55/100 (HOLD) and neutral sentiment (51/100) at $194.12 (in the middle of its 52-week range) describe a stock that is being considered rather than avoided.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).